ANTHEM.NS
ANTHEM.NS
INE0CZ201020
ANTHEM BIOSCIENCES LTD
Loading chart...

Company Profile

Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to commercial manufacturing for small molecules and biologics. It also manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company was incorporated in 2006 and is based in Bengaluru, India.

Related stocks

BIOCON.NS
BIOCON.NS • India
BIOCON LIMITED.
349.4 INR
5.91B USD 1Y +0.3%
002252.SZ
002252.SZ • China
SHANGHAI RAAS
5.06 CNY
4.99B USD 1Y -25.4%
688336.SS
688336.SS • China
SUNSHINE GUOJIAN PHARMACEUTICAL
38.1 CNY
5.11B USD 1Y +4.2%
603392.SS
603392.SS • China
BEIJING WANTAI BIOLOGICAL PHARM
26.96 CNY
5.1B USD 1Y -53.6%
300122.SZ
300122.SZ • China
ZHIFEI-BIOL
13.7 CNY
4.91B USD 1Y -34.6%
688180.SS
688180.SS • China
SHANGHAI JUNSHI BIOSCIENCES CO
33.83 CNY
5.19B USD 1Y -17.6%
1530.HK
1530.HK • China
3SBIO
15.07 HKD
4.76B USD 1Y -47.3%
9995.HK
9995.HK • China
REMEGEN
70.4 HKD
5.34B USD 1Y -33.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
3Y Volatility
-
Max Drawdown (3Y)
-
Sharpe Ratio (3Y)
-
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 85.0 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
ende